IN THE UNITED STATES PATENT AND TRADEMARK OFFICE					ATTORNEY DOCKET NO.:	T.NO.: SERIAL NO.:	
INFORMATION DISCLOSURE STATEMENT OFF \$1.56, §1.97, and §1.98				22491-0005	09/654,293		
PTO-1449 FORM				APPLICANTS: Christmann et al.			
MAR 2	6 2001 3)	SHEET 1 OF	1		FILING DATE:	GROUP ART UNIT:	
A TRA	TAADEMAN A			September 1, 2000	1632		
U.S. PATENT DOCUMENTS							
† EX'R INITIAL	*REF.#	PATENT NUMBER	DATE (MO/YR)		NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)
						REC	EIVED
						MAR	2 8 2001
							•
	i					IECH CENT	ER 1600/29 00
					1 A M C		
FOREIGN PATENT DOCUMENTS							
† EX'R INITIAL				COUNTRY		TRANSLATION (YES/NO)	
OTHER DOCUMENTS							
† EX'R INITIAL	*REF#						
TUT	. C37	Morrow, "Antibody-Production Technologies, With No Single Superior Approach, Companies Must Weigh Their Own Needs" Genetic Engineering News 20(7):1, 24-25, 54-55 (4/1/00)					
EXAMINER'S SIGNATURE DATE CONSIDERED 8120/04							
them							
					L		

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant.*

If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).